Dr. Salpeter has deep experience in developing and bringing new biotechnologies to market. He previously served as Co-Founder and CTO at Curesponse, a precision cancer medicine company. Prior to that he was Chief Scientist and VP Business Development at Sight Diagnostics. Dr. Salpeter holds a Ph.D in Biochemistry from the Hebrew University and performed post-doctoral studies at the Institute for Drug Research, the Hebrew University School of Pharmacy.

Dr. Granot is a world recognized expert in the field of neutrophil biology. Previously he identified the neutrophil’s role in anti-cancer activity and discovered the high and low density paradigm of neutrophil regulation suggesting that neutrophils can be repolarized. Recently he has focused his efforts on developing technologies for neutrophil modulation, leading to the founding of Immunyx. Dr. Granot received his Ph.D from the Hebrew University and performed Post-Doctoral work at Memorial Sloan Kettering.

Dr. Fridlender is a clinician with significant knowledge in the function of neutrophils in disease. His original work on neutrophils in cancer led to the discovery of the N1 and N2 phenotypes. His expertise ranges from internal medicine, pulmonology and basic immunological questions. He received his M.D from the Hebrew University Medical School and completed his fellowship at the University of Pennsylvania.

Dr. Naim is an expert in nanoparticle development and pre-clinical application. Previously she worked at BNS developing liposomes and polymers for use in targeted drug delivery. She received her Ph.D from the Hebrew University School of Pharmacy.

Dr. Julian Adams was previously CEO of Gamida Cell following his role as President and Chief Scientific Officer at Clal Biotechnology Industries (CBI). Before joining CBI, he served as the President of R&D at Infinity Pharmaceuticals, where he built and led the company’s R&D efforts. Julian served as Senior Vice President of Drug Discovery and Development at Millennium Pharmaceuticals, where he played a key role in the discovery of Velcade® (bortezomib. Earlier in his career, he was credited with discovering Viramune® (nevirapine) for HIV at BI. He is a world recognized expert in drug development and R&D.

Mr. Ori Choshen is the CEO of VLX Ventures bringing extensive, multidisciplinary experience in building innovation platforms and establishing, investing in and mentoring innovative startups in the life sciences, pharma, AI and hi-tech industries. Prior to joining VLX Ventures in 2013, Ori served as VP Business Development at Xenia VC and as a Director of Business Development at SanDisk, (NSDQ: SNDK) where he managed the Ecosystem Group. Ori joined SanDisk as part of the company’s $1.6 billion acquisition of M-Systems (NSDQ: FLSH) in 2006. Prior to this, Ori held business development and management positions at M-Systems and Hutchison’s global telecom group, managing the Handset Department (Marketing) of Orange Israel, a Hutchison’s subsidiary.

Ms. Moran Ben David brings with her a rich interdisciplinary background and skills at the cross-section of pharma drug development, biology and  business and IP law from blockbuster-drugs IP litigation, to evaluation of new technologies, biological and business opportunities as well as management of collaborations worldwide. Currently Moran is CBDO at VLX Ventures. Prior to joining VLX, Moran was Head of Business Development at Pharma Two B in Israel and held various business, strategy, and technological leadership positions in global strategic partnership and alliance management at GlaxoSmithKline, Novartis, and Takeda  in Boston. Moran is seasoned in establishing partnerships for early-stage innovative projects and clinical development.